Literature DB >> 10637505

ERK activation induces phosphorylation of Elk-1 at multiple S/T-P motifs to high stoichiometry.

F H Cruzalegui1, E Cano, R Treisman.   

Abstract

Elk-1, a member of the TCF family of Ets domain proteins, contains a C-terminal transcriptional activation domain with multiple copies of the MAPK core consensus sequence S/T-P. This region is phosphorylated by MAP kinases in vitro and in vivo, but the extent and kinetics of phosphorylation at the different sites have not been investigated in detail. We prepared antisera against the phosphorylated forms of residues T353, T363, T368, S383, S389 and T417. The antisera specifically recognize the phosphorylated Elk-1 C terminus and are specific for their cognate sites, as assessed by peptide competition and mutagenesis experiments. Analysis of cells stably expressing Elk-1 in vivo shows that following serum or TPA stimulation, residues T353, T363, T368, S383, S389 and T417 become phosphorylated with similar kinetics. Mutation of any one site does not prevent phosphorylation of the others. Mutation to alanine of S383, F378 or W379, which virtually abolishes transcriptional activation by Elk-1, does not affect phosphorylation of any sites tested. Analysis of Elk-1 using two-dimensional gel electrophoresis shows that following ERK activation Elk-1 receives at least six phosphates in addition to those present prior to stimulation. We propose that the Elk-1 C-terminal regulatory domain becomes stoichiometrically phosphorylated following growth factor stimulation.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10637505     DOI: 10.1038/sj.onc.1203362

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  67 in total

1.  ERF nuclear shuttling, a continuous monitor of Erk activity that links it to cell cycle progression.

Authors:  Lionel Le Gallic; Laura Virgilio; Philip Cohen; Benoit Biteau; George Mavrothalassitis
Journal:  Mol Cell Biol       Date:  2004-02       Impact factor: 4.272

2.  Cross-receptor interactions between dopamine D2L and neurotensin NTS1 receptors modulate binding affinities of dopaminergics.

Authors:  Susanne Koschatzky; Nuska Tschammer; Peter Gmeiner
Journal:  ACS Chem Neurosci       Date:  2011-04-11       Impact factor: 4.418

3.  Transcriptional Regulation of EGR1 by EGF and the ERK Signaling Pathway in Prostate Cancer Cells.

Authors:  Jennifer Gregg; Gail Fraizer
Journal:  Genes Cancer       Date:  2011-09

Review 4.  The ERK cascade: a prototype of MAPK signaling.

Authors:  Hadara Rubinfeld; Rony Seger
Journal:  Mol Biotechnol       Date:  2005-10       Impact factor: 2.695

5.  Overexpression of Ets-like protein 1 in human esophageal squamous cell carcinoma.

Authors:  An-Guo Chen; Zai-Cheng Yu; Xin-Feng Yu; Wen-Feng Cao; Fang Ding; Zhi-Hua Liu
Journal:  World J Gastroenterol       Date:  2006-12-28       Impact factor: 5.742

6.  Activation of p90 Rsk1 is sufficient for differentiation of PC12 cells.

Authors:  Eran Silverman; Morten Frödin; Steen Gammeltoft; James L Maller
Journal:  Mol Cell Biol       Date:  2004-12       Impact factor: 4.272

7.  Histone deacetylase 3 suppresses Erk phosphorylation and matrix metalloproteinase (Mmp)-13 activity in chondrocytes.

Authors:  Lomeli R Carpio; Elizabeth W Bradley; Jennifer J Westendorf
Journal:  Connect Tissue Res       Date:  2016-09-23       Impact factor: 3.417

Review 8.  Extracellular-Regulated Kinases: Signaling From Ras to ERK Substrates to Control Biological Outcomes.

Authors:  Scott T Eblen
Journal:  Adv Cancer Res       Date:  2018-03-02       Impact factor: 6.242

9.  Interaction of serum response factor (SRF) with the Elk-1 B box inhibits RhoA-actin signaling to SRF and potentiates transcriptional activation by Elk-1.

Authors:  Kasumi Murai; Richard Treisman
Journal:  Mol Cell Biol       Date:  2002-10       Impact factor: 4.272

10.  Epitope-guided engineering of monobody binders for in vivo inhibition of Erk-2 signaling.

Authors:  Jasdeep K Mann; Jordan F Wood; Anne Fleur Stephan; Emmanuel S Tzanakakis; Denise M Ferkey; Sheldon Park
Journal:  ACS Chem Biol       Date:  2012-12-18       Impact factor: 5.100

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.